Axsome Therapeutics price target raised to $195 from $137 at Mizuho

Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following the patent settlement with Teva (TEVA). The firm removed the impact of a previously anticipated 2034 launch of a generic version of Auvelity within its 2025 to 2037 forecast period. With no other generic challengers expected, this is a “major positive” for Axsome, the analyst tells investors in a research note. Mizuho says the company’s attractiveness to potential strategics “could now meaningfully increase,” while the news should help remove a long-standing overhang on the shares.